TYCHE INDUSTRIES | GLENMARK PHARMA | TYCHE INDUSTRIES/ GLENMARK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 15.3 | -42.4 | - | View Chart |
P/BV | x | 1.6 | 5.4 | 29.3% | View Chart |
Dividend Yield | % | 1.3 | 0.2 | 765.7% |
TYCHE INDUSTRIES GLENMARK PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TYCHE INDUSTRIES Mar-24 |
GLENMARK PHARMA Mar-24 |
TYCHE INDUSTRIES/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 219 | 974 | 22.5% | |
Low | Rs | 137 | 464 | 29.6% | |
Sales per share (Unadj.) | Rs | 67.8 | 418.6 | 16.2% | |
Earnings per share (Unadj.) | Rs | 11.9 | -64.9 | -18.4% | |
Cash flow per share (Unadj.) | Rs | 13.8 | -44.3 | -31.3% | |
Dividends per share (Unadj.) | Rs | 2.50 | 2.50 | 100.0% | |
Avg Dividend yield | % | 1.4 | 0.3 | 403.7% | |
Book value per share (Unadj.) | Rs | 123.6 | 277.5 | 44.6% | |
Shares outstanding (eoy) | m | 10.25 | 282.19 | 3.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.6 | 1.7 | 152.8% | |
Avg P/E ratio | x | 14.9 | -11.1 | -134.5% | |
P/CF ratio (eoy) | x | 12.9 | -16.3 | -79.2% | |
Price / Book Value ratio | x | 1.4 | 2.6 | 55.6% | |
Dividend payout | % | 20.9 | -3.9 | -542.9% | |
Avg Mkt Cap | Rs m | 1,825 | 202,964 | 0.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 78 | 28,681 | 0.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 695 | 118,131 | 0.6% | |
Other income | Rs m | 59 | 8,400 | 0.7% | |
Total revenues | Rs m | 754 | 126,531 | 0.6% | |
Gross profit | Rs m | 126 | 2,944 | 4.3% | |
Depreciation | Rs m | 19 | 5,819 | 0.3% | |
Interest | Rs m | 0 | 5,160 | 0.0% | |
Profit before tax | Rs m | 166 | 365 | 45.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 44 | 18,673 | 0.2% | |
Profit after tax | Rs m | 122 | -18,309 | -0.7% | |
Gross profit margin | % | 18.2 | 2.5 | 730.2% | |
Effective tax rate | % | 26.4 | 5,116.7 | 0.5% | |
Net profit margin | % | 17.6 | -15.5 | -113.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,167 | 74,281 | 1.6% | |
Current liabilities | Rs m | 103 | 58,186 | 0.2% | |
Net working cap to sales | % | 153.0 | 13.6 | 1,123.2% | |
Current ratio | x | 11.3 | 1.3 | 888.9% | |
Inventory Days | Days | 31 | 31 | 100.2% | |
Debtors Days | Days | 1,004 | 57 | 1,748.5% | |
Net fixed assets | Rs m | 239 | 58,808 | 0.4% | |
Share capital | Rs m | 102 | 282 | 36.3% | |
"Free" reserves | Rs m | 1,165 | 78,015 | 1.5% | |
Net worth | Rs m | 1,267 | 78,297 | 1.6% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,405 | 133,089 | 1.1% | |
Interest coverage | x | 8,315.5 | 1.1 | 776,619.0% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.5 | 0.9 | 55.7% | |
Return on assets | % | 8.7 | -9.9 | -88.2% | |
Return on equity | % | 9.7 | -23.4 | -41.3% | |
Return on capital | % | 13.1 | 7.1 | 186.0% | |
Exports to sales | % | 64.6 | 0 | - | |
Imports to sales | % | 10.9 | 0 | - | |
Exports (fob) | Rs m | 449 | NA | - | |
Imports (cif) | Rs m | 76 | NA | - | |
Fx inflow | Rs m | 449 | 32,207 | 1.4% | |
Fx outflow | Rs m | 89 | 19,636 | 0.5% | |
Net fx | Rs m | 359 | 12,571 | 2.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 77 | -2,654 | -2.9% | |
From Investments | Rs m | 39 | 45,609 | 0.1% | |
From Financial Activity | Rs m | -20 | -39,061 | 0.1% | |
Net Cashflow | Rs m | 96 | 2,152 | 4.5% |
Indian Promoters | % | 62.0 | 46.7 | 132.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 36.3 | - | |
FIIs | % | 0.0 | 23.1 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 38.0 | 53.4 | 71.3% | |
Shareholders | 7,264 | 193,949 | 3.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare TYCHE INDUSTRIES With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | TYCHE INDUSTRIES | Glenmark Pharma | S&P BSE IT |
---|---|---|---|
1-Day | -0.66% | 0.97% | 0.42% |
1-Month | 8.36% | -10.18% | 3.12% |
1-Year | 11.42% | 93.81% | 31.23% |
3-Year CAGR | 3.95% | 41.30% | 7.69% |
5-Year CAGR | 20.05% | 33.71% | 23.52% |
* Compound Annual Growth Rate
Here are more details on the TYCHE INDUSTRIES share price and the Glenmark Pharma share price.
Moving on to shareholding structures...
The promoters of TYCHE INDUSTRIES hold a 62.0% stake in the company. In case of Glenmark Pharma the stake stands at 46.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of TYCHE INDUSTRIES and the shareholding pattern of Glenmark Pharma.
Finally, a word on dividends...
In the most recent financial year, TYCHE INDUSTRIES paid a dividend of Rs 2.5 per share. This amounted to a Dividend Payout ratio of 20.9%.
Glenmark Pharma paid Rs 2.5, and its dividend payout ratio stood at -3.9%.
You may visit here to review the dividend history of TYCHE INDUSTRIES, and the dividend history of Glenmark Pharma.
For a sector overview, read our software sector report.
Asian stocks experienced a notable rally alongside US equity futures on Monday, marking a positive turn for the markets. The dollar retreated against other currencies as bond yields declined.